• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • Arimidex
    • Crestor
    • Nexium
    • Seroquel
    • Symbicort
    • All Drug Products
  • Diseases & Conditions
    • Acid Reflux (Heart Burn)
    • High Cholesterol
    • Asthma
    • Breast Cancer
    • Bipolar Disorder
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Drug Products
  • Seroquel

Drug Status: Marketed Drug

Seroquel (quetiapine) is an atypical antipsychotic medication indicated for the treatment of schizophrenia, and for the treatment of acute manic episodes associated with bipolar disorder.

For further information on Seroquel and links to other product specific and disease area websites please click here.

Please consult the prescribing information for the country concerned on the approved use of drug. 

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • collapse Effectiveness of atypical antipsychotics on anhedonic features in patients with schizophrenia
  • collapse Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
  • collapse A Local Non Interventional Retrospective Register Study of the Current Clinical Treatment Practices and the Number of Hospitalization Days With Seroquel or Seroquel Prolong.
  • collapse SERENITY: Evaluating the effectiveness of atypical antipsychotics in the community – a prospective, multicentre, observational study to evaluate the impact on Quality of Life of GP-based management of antipsychotic treatment in Belgium.
  • collapse A Multicenter, Rand., Double-blind, Parallel-group, Pbo-controlled Study of the Efficacy and Safety of SEROQUEL XR Compared with Pbo as an Adjunct to Treatment in Patients with Generalized Anxiety Disorder who Demonstrate Partial or No Response to a SSRI or SNRI Alone or in Combination with a Benzo.
  • collapse Non-interventional study to obSERve currENtmanagement of Index episode in patients with bipolar disorder Treated bY Seroquel XR
  • collapse Non-interventional study to observe efficacy and usage of quetiapine in acute episodes of schizophrenia and as maintenance therapy following standard clinical practice in Croatia
  • collapse Evaluation of treatment outcomes in schizophrenic patients taking part in the integrated care program - a single-country, multi-centre non-interventional study.
  • collapse A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium versus Placebo as an add on to SEROQUEL XR (Quetiapine Fumarate) in Adult Patients with Acute Mania
  • collapse A Randomized, Open-label Trial to Evaluate the Pharmacokinetics of Extended-Release (XR) Quetiapine Fumarate 300 mg, 600 mg and 800 mg in Chinese schizophrenic patients
  • Pages
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2010